HUTCHMED (China) (HCM) Equity Ratio (2015 - 2025)

HUTCHMED (China) (HCM) reported Equity Ratio of 5.55 for Q4 2025, up 693.81% quarter-over-quarter from 0.7 in Q2 2025.

HUTCHMED (China) (HCM) Equity Ratio (2015 - 2025) Analysis & Trends

HUTCHMED (China) (HCM) has 11 years of Equity Ratio data on file, last reported at 5.55 in Q4 2025.

Equity Ratio for Q4 2025 came in at 5.55, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was 5.55 (changed N/A YoY), and the FY2025 annual result was 5.55, changed N/A from the prior year.
Equity Ratio improved to 5.55 in Q4 2025 per HCM's latest filing, from 0.7 in the prior quarter.
Over five years, Equity Ratio peaked at 5.9 in Q4 2021 and troughed at 0.67 in Q1 2021.
A 5-year average of 3.18 and a median of 4.66 in 2024 frame the typical range for Equity Ratio.
The sharpest annual moves came in 2021 and 2025: Equity Ratio soared 609.43% in 2021, then tumbled 85.0% in 2025.
A 5-year view of Equity Ratio shows it stood at 5.9 in 2021, then declined by 17.96% to 4.84 in 2022, then decreased by 0.11% to 4.83 in 2023, then decreased by 3.54% to 4.66 in 2024, then rose by 19.06% to 5.55 in 2025.
Business Quant data shows HCM's Equity Ratio at 5.55 in Q4 2025, 0.7 in Q2 2025, and 4.66 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Ratio (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	0.21
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	0.21
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	0.88
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	0.73
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	0.69
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	0.49
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	0.41
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	0.52
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	0.20
10	HUTCHMED (China)	1.20 Bn	-273.24 Mn	-	5.55

Download Data